ArticleFrontiers in nutrition2025
Leveraging the enrichment analysis from a genome-wide association study against epilepsy-focusing on the role of tryptophan catabolites pathway in patients with drug-resistant epilepsy.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant epilepsy (DRE) is a chronic neurological disorder with somatic impacts and an increased risk of psychiatric comorbidities and cognitive impairment. Previous studies suggested that genomic variants could contribute to the high interindividual variability in epilepsy and in its treatment response, but it remains unclear. Here, we aimed to perform genome-wide association study (GWAS), leverage the enrichment analysis of the genomic variants, and provide the potential molecular signature profiles. Moreover, we investigated the potential role of molecular signature profiles, as exemplified by tryptophan catabolites (TRYCATs), in DRE patients. Methods: We used data from the Taiwan Biobank to perform a GWAS and identified enrichment pathways through the functional database Reactome. To validate the results, we enrolled community-dwelling controls and DRE patients. The levels of TRYCATs were determined using liquid chromatography-tandem mass spectrometry. In addition, we compared the levels of TRYCATs between the controls and DRE patients at baseline and after 6-month multivitamin supplementation. Seizure frequency was defined as the number of episodes per 28 days in DRE patients. Results: Using GWAS and enrichment analysis of genomic data, we obtained candidate genes implicated in mechanisms and molecular signature profiles against epilepsy, such as the TRYCATs pathway. To validate the molecular signature from enrichment analysis, we further examined whether the TRYCATs pathway was associated with the pathophysiology of epilepsy and treatment outcome in DRE patients. We found that DRE patients had significantly lower levels of TRYCATs (tryptophan, serotonin, 3-indole acetic acid, 3-indoleperopionic acid, kynurenine, and kynurenic acid) than the controls. Additionally, changes in the balance of the TRYCATs pathway were noted in DRE patients treated with 6-month multivitamin supplementation. Furthermore, the change levels of TRYCATs were correlated with seizure frequency in the DRE patients during multivitamin supplementation. Conclusion: The TRYCATs pathway plays an important role in the pathophysiology of epilepsy and is involved in the multivitamin-mediated physiological alterations in DRE patients. Therefore, the balance of TRYCATs might be a new biomarker and therapeutic strategy for epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.